open access

Vol 82, No 3 (2011)
ARTICLES
Get Citation

Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate

Tomasz Milewicz, Józef Krzysiek, Iwona Rogatko, Krystyna Sztefko, Ewa Stochmal, Alicja Hubalewska-Dydejczyk, Robert Jach, Stanisław Radowicki
Ginekol Pol 2011;82(3).

open access

Vol 82, No 3 (2011)
ARTICLES

Abstract

Abstract Aim: The aim of the present work was to assess the influence of estradiol administration mode on the plasma IGF-I, IGFBP-1, IGFBP-3 levels in postmenopausal women treated with norethisterone acetate. Material and methods: 39 women were enrolled into the study. Group A – 14 women received transdermal 17β-estradiol (Oesclim 50 – Fournier-Solvay) combined with oral norethisterone 2.5mg daily (Primolut-Nor – Schering), Group B – 10 women on oral 2mg 17β-estradiol combined with oral 1 mg daily norethisterone (Kliogest – Novo-Nordisk). Control group (group C) consisted of 15 postmenopausal women who received no treatment. Basic plasma FSH, estradiol and total IGF-I, IGFBP-1 as well as IGFBP-3 levels were measured initially and at the 52nd week of the study. Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in groups A and B during hormone therapy. Mean plasma levels of total IGF-I, IGFBP-1, IGFBP-3 as well as IGFBP-3/IGF-I ratio did not changed significantly during 52 weeks of observation in groups A, B and C. The comparison of plasma IGF-I, IGFBP-1, IGFBP-3 between groups at the initial visit and after 52 weeks showed the lowest concentration f IGBP-3 in group B. Other parameters showed no differences among the three groups. Conclusion: Mode of administration of estradiol did not influenced the plasma levels of IGF-I, IGFBP-1, IGFBP-3 in postmenopausal women treated with norethisterone acetate.

Abstract

Abstract Aim: The aim of the present work was to assess the influence of estradiol administration mode on the plasma IGF-I, IGFBP-1, IGFBP-3 levels in postmenopausal women treated with norethisterone acetate. Material and methods: 39 women were enrolled into the study. Group A – 14 women received transdermal 17β-estradiol (Oesclim 50 – Fournier-Solvay) combined with oral norethisterone 2.5mg daily (Primolut-Nor – Schering), Group B – 10 women on oral 2mg 17β-estradiol combined with oral 1 mg daily norethisterone (Kliogest – Novo-Nordisk). Control group (group C) consisted of 15 postmenopausal women who received no treatment. Basic plasma FSH, estradiol and total IGF-I, IGFBP-1 as well as IGFBP-3 levels were measured initially and at the 52nd week of the study. Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in groups A and B during hormone therapy. Mean plasma levels of total IGF-I, IGFBP-1, IGFBP-3 as well as IGFBP-3/IGF-I ratio did not changed significantly during 52 weeks of observation in groups A, B and C. The comparison of plasma IGF-I, IGFBP-1, IGFBP-3 between groups at the initial visit and after 52 weeks showed the lowest concentration f IGBP-3 in group B. Other parameters showed no differences among the three groups. Conclusion: Mode of administration of estradiol did not influenced the plasma levels of IGF-I, IGFBP-1, IGFBP-3 in postmenopausal women treated with norethisterone acetate.
Get Citation

Keywords

IGF-I, IGFBP-3, IGFBP-1, estradiol, norethisterone

About this article
Title

Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate

Journal

Ginekologia Polska

Issue

Vol 82, No 3 (2011)

Bibliographic record

Ginekol Pol 2011;82(3).

Keywords

IGF-I
IGFBP-3
IGFBP-1
estradiol
norethisterone

Authors

Tomasz Milewicz
Józef Krzysiek
Iwona Rogatko
Krystyna Sztefko
Ewa Stochmal
Alicja Hubalewska-Dydejczyk
Robert Jach
Stanisław Radowicki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl